This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
NK4 (Protein Therapy)
Kringle Pharma, Inc.
Drug Names(s): NK4 (Protein Therapy)
Kringle is developing NK4 as a gene and protein therapy.
NK4 is a competitive antagonist of the HGF/cMet interaction. It is composed an N-terminal hairpin domain and four K-domains from HGF. Thus, it contains the cMet receptor binding domain but lacks biological activity. That is, it displaces HGF binding to cMet receptor but does not activate the receptor.
In October 2005, Biolex Therapeutics Kringle Pharma formed a collaboration under which Biolex will use its LEX System for protein expression to create a commercial line for Kringle's NK4 protein.
By December 2012, Kringle Pharma no longer listed a partner on its NK4 protein program in its pipeline.
NK4 (Protein Therapy) News
Additional information available to subscribers only: